Mark Zuckerberg backed Cellular Intelligence buys Novo Nordisk Parkinson cell therapy after shutdown

Novo Nordisk had stopped the therapy last October

Mark Zuckerberg backed Cellular Intelligence has acquired Novo Nordisk’s Parkinson’s cell therapy after the Danish drugmaker shut down its cell therapy unit last October. Novo Nordisk said the restructuring meant discontinuing development of the therapy. The deal signals renewed interest in the approach and could reshape the therapy’s next development and commercialization plans.